Continuous monitoring of Naproxen by a cytochrome P450-based electrochemical sensor

被引:53
作者
Baj-Rossi, C. [1 ]
Jost, T. Rezzonico [2 ]
Cavallini, A. [1 ]
Grassi, F. [2 ]
De Micheli, G. [1 ]
Carrara, S. [1 ]
机构
[1] Ecole Polytech Fed Lausanne, EPFL, Integrated Syst Lab, Lausanne, Switzerland
[2] Inst Res Biomed IRB, Bellinzona, Switzerland
基金
瑞士国家科学基金会;
关键词
Cytochrome P450; Continuous drug monitoring; Electrochemical biosensors; Carbon nanotubes; Personalized therapy; DIRECT ELECTRON-TRANSFER; HUMAN SERUM; BIOSENSORS; PHARMACOKINETICS; CYP3A4;
D O I
10.1016/j.bios.2013.09.058
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
This paper reports the characterization of an electrochemical biosensor for the continuous monitoring of Naproxen based on cytochrome P450. The electrochemical biosensor is based on the drop-casting of multi-walled carbon-nanotubes (MWCNTs) and microsomal cytochrome P4501A2 (msCYP1A2) on a graphite screen-printed electrode (SPE). The proposed biosensor was employed to monitor Naproxen (NAP), a well-known anti-inflammatory compound, through cyclic voltammetry. The dynamic linear range for the amperometric detection of NAP had an upper limit of 300 mu M with a corresponding limit of detection (LOD) of 16 +/- 1 mu M (S/N=3), which is included in NAP physiological range (9-300 mu M). The MWCNT/msCYP1A2-SPE sensor was also calibrated for NAP detection in mouse serum that was previously extracted from mice, showing a slightly higher LOD (33 +/- 18 mu M). The stability of the msCYP1A2-based biosensor was assessed by longtime continuous cyclic voltammetric measurements. The ability of the sensor to monitor drug delivery was investigated by using a commercial micro-osmotic pump. Results show that the MWCNT/msCYP1A2-SPE sensor is capable of precisely monitoring the real-time delivery of NAP for 16 h. This work proves that the proposed electrochemical sensor might represent an innovative point-of-care solution for the personalization of drug therapies, as well as for pharmacokinetic studies in both animals and humans. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:283 / 287
页数:5
相关论文
共 36 条
  • [1] Antonini M, 2003, IEE Proc Nanobiotechnol, V150, P31, DOI 10.1049/ip-nbt:20030534
  • [2] PHARMACOKINETICS OF NAPROXEN IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
    ANTTILA, M
    HAATAJA, M
    KASANEN, A
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 18 (03) : 263 - 268
  • [3] Aspinall MG, 2007, HARVARD BUS REV, V85, P108
  • [4] Electrochemical Detection of Anti-Breast-Cancer Agents in Human Serum by Cytochrome P450-Coated Carbon Nanotubes
    Baj-Rossi, Camilla
    De Micheli, Giovanni
    Carrara, Sandro
    [J]. SENSORS, 2012, 12 (05) : 6520 - 6537
  • [5] Carrara S., 2009, P ICME INT C COMPL M, P1
  • [6] Multi-panel drugs detection in human serum for personalized therapy
    Carrara, Sandro
    Cavallini, Andrea
    Erokhin, Victor
    De Micheli, Giovanni
    [J]. BIOSENSORS & BIOELECTRONICS, 2011, 26 (09) : 3914 - 3919
  • [7] Biosensors in clinical chemistry-2011 update
    D'Orazio, Paul
    [J]. CLINICA CHIMICA ACTA, 2011, 412 (19-20) : 1749 - 1761
  • [8] Epoxidation of styrene by human cyt P450 1A2 by thin film electrolysis and peroxide activation compared to solution reactions
    Estavillo, C
    Lu, ZQ
    Jansson, I
    Schenkman, JB
    Rusling, JF
    [J]. BIOPHYSICAL CHEMISTRY, 2003, 104 (01) : 291 - 296
  • [9] Implantable chemical sensors for real-time clinical monitoring: progress and challenges
    Frost, MC
    Meyerhoff, ME
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (05) : 633 - 641
  • [10] Continuous glucose monitoring: A review of biochemical perspectives and clinical use in type 1 diabetes
    Girardin, Celine M.
    Huot, Celine
    Gonthier, Monique
    Delvin, Edgard
    [J]. CLINICAL BIOCHEMISTRY, 2009, 42 (03) : 136 - 142